This analysis examines the historical and forecast performance for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Pfizer's performance against key rivals in the ethical pharmaceutical sector Assess the impact of patent expiry for Lipitor on the commercial outlook of Pfizer over 2006-12 Analyze the potential strategies that could be used by Pfizer to improve sales growth credentials in light of heavy exposure to generic competition.